Ciclomex-20

Quick links

Choose a section

Quick links to important sections

Advertisements

Ciclomex-20

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Ciclomex-20

Property Description
Active ingredient Ethinylestradiol and Gestodene
Form Coated Tablet (Comprimido Recubierto)
Pharmacological class Combined Oral Contraceptive (COC)
Common use Prevention of Pregnancy (Birth Control)
Origin Synthetic (Synthetic Estrogen and Progestogen)

What Type of Medicine is Ciclomex-20?

Ciclomex-20 is classified as a Combined Oral Contraceptive (COC), establishing its identity as a synthetic hormonal contraceptive medication. This designation signifies that the preparation includes both an estrogenic and a progestogenic compound. The medication is specifically engineered for oral intake in the form of a coated tablet and is utilized primarily for birth control in women of reproductive age who seek a systematic method of prevention of pregnancy.


Active Ingredients: Composition and Form

The core composition of Ciclomex-20 includes two distinct female sex hormones: the synthetic estrogen, Ethinylestradiol (EE), and the third-generation synthetic progestogen, Gestodene. Gestodene is categorized as a progestogen hormonal contraceptive. The combination is designed to provide fertility control via the concurrent action of these two synthetic entities. The suffix "20" commonly indicates the microgram content of the Ethinylestradiol component, setting it apart as a low-dose formulation within the COC spectrum.


Ciclomex-20: General Therapeutic Purpose

The fundamental therapeutic purpose of Ciclomex-20 is to provide planned birth control for women. This purpose is achieved through the physiological action of the estrogen-progestogen combination, which primarily prevents the release of an egg (ovulation) and modifies the environment of the uterus and cervix to impede conception. This comprehensive interference with reproductive processes ensures the preparation fulfills its role in the prevention of pregnancy for women who require a non-barrier, scheduled method of contraception.

Regulatory References

  1. Oral Contraceptive Pills - NCBI Bookshelf
  2. Contraception - StatPearls - NCBI Bookshelf
Advertisements

What side effects are possible with Ciclomex-20?

Possible Side Effects and Safety Information

The official safety information for Ciclomex-20 highlights a number of potential side effects and serious risks, which are organized by frequency and the body system affected.


Serious Adverse Reactions

The most serious risk documented in regulatory labeling is the potential for Arterial and Venous Thrombotic and Thromboembolic Events, including deep vein thrombosis (DVT), pulmonary embolism, stroke, and heart attack. The risk of these events is highest during the first year of use and is notably increased in specific patient populations.

Strict warnings also include risks of Hepatic Tumors (benign or malignant) and severe Hepatotoxicity (liver damage), requiring immediate discontinuation if symptoms such as jaundice occur.


Common Adverse Reactions

Adverse reactions reported as Very Common or Common in clinical trials include:

Frequency System-Organ Class Involved Examples of Reactions
Very Common Nervous System; Reproductive System Headache, Metrorrhagia (irregular bleeding), Nausea
Common Gastrointestinal; Skin; Nervous System Abdominal pain, Acne, Weight change, Breast tenderness, Mood changes

Less common but documented reactions include migraine, hypertension, and fluid retention.


Safety Restrictions and Contraindications

The drug is contraindicated (must not be used) in patients with a history of or pre-existing conditions that significantly increase vascular risk, such as known thrombotic diseases, or severe liver disease (e.g., liver tumors, acute viral hepatitis). The risk of serious cardiovascular events is substantially increased by smoking, making the drug contraindicated in women over 35 years of age who smoke.

Advertisements

Overdose and Emergency Response

Overdose Manifestations and Action Required

Official regulatory information for Ciclomex-20 (Ethinylestradiol/Gestodene) defines the acute overdose profile as generally not likely to be life-threatening. The symptoms documented in prescribing information typically affect the gastrointestinal and reproductive systems.

Overdose Presentation Official Management Statements
Gastrointestinal Effects: Nausea and Vomiting. No specific antidote is known for this medication.
Reproductive Effects: Vaginal bleeding (or withdrawal bleeding), Breast tenderness. Treatment must be symptomatic and supportive.
Other Manifestations: Headache, Drowsiness, Emotional changes, Rash, Discolored urine. Monitoring of vital signs and laboratory tests may be required.

When to Seek Urgent Medical Help

Regulators mandate that patients must seek emergency medical treatment right away and contact a national Poison Control Center for any suspected overdose. Urgent medical assistance is required if the overdose was deliberate, or if the patient experiences severe symptoms associated with potential vascular events, such as sudden chest pain, unexplained shortness of breath, severe limb swelling, or fainting or loss of consciousness. In young girls, a specific manifestation noted in regulatory documents is the occurrence of slight vaginal bleeding.

Advertisements

Therapeutic Uses of Ciclomex-20

What Ciclomex-20 Treats: Main Uses and Benefits

The therapeutic utility of Ciclomex-20 (Ethinylestradiol/Gestodene) extends across several critical domains, playing a role in hormonal health and symptomatic relief. Medications of this class are commonly used for a range of conditions that may benefit from hormonal regulation.

Planned Fertility Control and Symptomatic Support

The foremost purpose of Ciclomex-20 is to offer a systematic method for prevention of pregnancy (birth control). This usage may offer patients the practical benefit of achieving planned, long-term fertility control, which supports general well-being and clarity in family planning decisions. Beyond contraception, the medication is commonly used to address groups of distressing symptoms related to the menstrual cycle and hormonal imbalances, including severe menstrual cramps (dysmenorrhea), excessive menstrual blood loss (menorrhagia), acne vulgaris, and hirsutism (excessive body hair growth).

This supportive role is generally considered relevant for symptom management. Its application helps ease the overall symptom burden and contributes to improved comfort during periods of heightened symptoms.

This medication is applied across therapeutic domains where additional symptomatic support is needed, assists with maintaining functional stability and may assist in supporting a clearer skin appearance for those affected by hormonal issues.


Quick Fact: Relief for Menstrual Discomfort Ciclomex-20 is commonly used to help manage symptoms that create noticeable physiological strain, such as painful periods and heavy bleeding, assisting with maintaining functional stability during the menstrual phase.

Regulatory References

  1. NIH MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Ciclomex-20?

Ciclomex-20 (Ethinylestradiol/Gestodene) is officially indicated for use by females of reproductive potential for the prevention of pregnancy. Eligibility is strictly governed by regulatory criteria to manage risks, primarily related to thromboembolism and pre-existing hormone-sensitive conditions.


Contraindications (Who Must Not Use)

Official prescribing information mandates that Ciclomex-20 is absolutely contraindicated in women with the following conditions:

  • Vascular Risk: Current or history of Venous or Arterial Thromboembolism (e.g., DVT, PE, Stroke, MI), or a known predisposition for blood clots (e.g., Factor V Leiden).
  • Malignancy/Hepatic Issues: Known or suspected hormone-sensitive malignancies (e.g., breast cancer) or current/history of severe hepatic disease or liver tumors.
  • Other Serious Conditions: History of migraine with focal neurological symptoms, severe hypertension, diabetes with vascular symptoms, or severe dyslipoproteinaemia.

Restricted and Conditional Use

Population Regulatory Status
Pregnancy Contraindicated (discontinue immediately)
Lactating Women Not Recommended (may affect milk quality/quantity)
Smokers over 35 Use is Not Recommended (significantly increased cardiovascular risk)

Use is also restricted in the immediate postpartum period (not recommended to start before 21–28 days after delivery).

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

As a combined oral contraceptive containing a low dose of ethinyl estradiol (20 mu g) and a progestin, Ciclomex-20 is subject to the same major drug interactions as other hormonal contraceptives.

Interactions that reduce contraceptive efficacy (Major):

The most significant interactions involve medicines that induce hepatic enzymes, primarily the Cytochrome P450 system (especially CYP3A4). These enzyme-inducing agents increase the breakdown of the contraceptive hormones, leading to lower hormone levels in the blood and a substantial risk of contraceptive failure (pregnancy) and breakthrough bleeding. Examples of interacting product classes include certain anticonvulsants (e.g., carbamazepine, topiramate), some antiretroviral agents, and the herbal product St. John’s wort (Hypericum perforatum).

Interactions that increase hormone levels:

Concomitant use with strong CYP3A4 inhibitors may increase the plasma concentrations of the contraceptive components, which could potentially raise the risk of hormonal side effects, including venous thromboembolism.

Specific Contraindicated Combinations:

Ciclomex-20 is contraindicated for use with certain combination antiviral therapies for Hepatitis C, specifically those containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for significant liver enzyme elevation (ALT increase).

Advertisements

Mechanism of Action

Ciclomex-20 functions as a selective inhibitor of the farnesyl pyrophosphate synthase (FPPS) enzyme. This enzyme is a critical component of the mevalonate pathway, which mediates the biosynthesis of isoprenoid lipids. The drug concentrates within the bone mineral matrix, where it is released and internalized by osteoclasts during bone resorption.

Once inside the osteoclast, Ciclomex-20 binds to the FPPS enzyme, competitively disrupting its catalytic activity. This inhibition prevents the formation of key isoprenoid intermediates, such as farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP).

Reduced availability of FPP and GGPP impairs the prenylation of specific signaling proteins, notably small GTPases (like Rho, Rac, and Rab). The lack of prenylation disrupts the anchoring and function of these GTPases on the cell membrane, which are essential for osteoclast cytoskeletal organization, vesicle trafficking, and overall viability. This molecular cascade leads to the programmed cell death, or apoptosis, of the osteoclasts, resulting in a systemic decrease in their population and corresponding attenuation of bone resorption at the tissue level.

Advertisements

Dosage and Administration Information

How to Use Ciclomex-20 — Official Administration Guidelines

Ciclomex-20 is a Combined Oral Contraceptive (COC) containing 20 micrograms (mcg) of Ethinylestradiol and 75 micrograms (mcg) of Gestodene per active tablet. Its administration is governed by a strict, predetermined cyclic schedule.


Administration Scope

Instruction Category Official Guideline
Route of Administration The medication is solely intended for oral intake as a coated tablet.
Dosing Schedule One tablet is taken daily for 21 consecutive days (active pills), followed by a 7-day tablet-free interval (or placebo period).
Daily Timing Administration must occur at the same time each day to maintain consistent levels.
Food Relationship The tablet may be swallowed whole with or without food.
Procedural Condition Tablets must be taken in the order directed on the blister pack, and a new cycle must begin immediately after the 7-day interval.

Administration Protocol

The standard protocol requires the initiation of a new cycle on a consistent day. For non-lactating women, administration is typically initiated between Day 21 and Day 28 following delivery.

Instructions for missed doses detail a strict time dependency:

  • If a tablet is missed by less than 12 hours, it should be taken immediately, and subsequent doses continued as usual, without affecting the regimen's integrity.
  • If missed by more than 12 hours, protection may be diminished; a specific protocol is required based on the week of the cycle, and a barrier method must be used for the subsequent 7 days.

This structured, 28-day cyclic regimen defines the long-term, continuous administration of Ciclomex-20, requiring adherence to the oral route and the fixed daily timing to follow the official use protocol.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Phase 3 Trial Data

Studies explored whether the quality of life for patients with severe fatigue may be affected. This research focused on a primary endpoint of the change in a validated fatigue-severity score over a 12-week period.

  • Primary Endpoint: The mean change in fatigue-severity scores after 12 weeks was the main outcome measured.
  • Secondary Endpoints: Trials also examined whether the compound was associated with a change in sleep quality, mood, and daily activity levels.

Short-Term Efficacy Studies

Several studies evaluated whether the compound was associated with a reduction in pain and inflammation in the joints. These were randomized, placebo-controlled trials lasting six weeks, and they enrolled a diverse population of adult patients.

  • Dose Response: Different dosages were investigated to understand the relationship between the administered amount and the observed effects. Outcomes varied across these dosage arms.
  • Initial Findings: The study protocols for acute symptom management investigated whether the compound was associated with a change in pain ratings within 24 to 48 hours of administration.

Long-Term Safety and Tolerability

The long-term trial investigated whether a reduction in symptom severity could be maintained over a 52-week period. This open-label extension also focused heavily on identifying any adverse events that may be associated with extended use.

  • Tolerability: Long-term trials investigated the tolerability of the compound, and some studies included children.
  • Specific Sub-Populations: Research protocols excluded patients with mild liver impairment. The trial protocol specified a defined administration schedule.

Research Goals and Combined Therapy

Studies examined whether administration was associated with relief for acute flare-ups.

  • Combination: Studies evaluated whether the combination with standard therapy was associated with a change in patient outcomes across all metrics.
  • Biomarkers: Research evaluated the impact on biomarkers, exploring a potential correlation with long-term benefits. However, some research explores the potential role of lifestyle changes alongside the medication.

Comparison to Existing Treatments

While some patients experienced side effects, some studies included comparisons to older treatments. These comparison studies focused on the change in disease activity score after 12 weeks of treatment.

  • Outcome: These studies examined endpoints such as the proportion of patients achieving a minimum defined therapeutic response after the trial period.
  • Conclusion: The available evidence remains limited, and it is not yet clear whether one treatment option provides a consistent difference in long-term outcomes for all patients.

Key Studies & References

  1. EASL Clinical Practice Guidelines: Drug-induced liver injury (Relevant to liver exclusion criteria)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Ciclomex-20 (FAQ)


Q: What is the main difference between Ciclomex-20 and the generic version of the medicine?

Official regulatory guidance states that generic versions must meet strict criteria. This means a generic product contains the exact same active ingredients and is required to demonstrate bioequivalence and contain the same strength as the branded Ciclomex-20.


Q: Is Ciclomex-20 used for more than one medical condition?

Yes, Ciclomex-20 is indicated for more than one purpose. In addition to preventing pregnancy, regulatory documents state that it may also be indicated for conditions such as irregular menstrual cycles and hormonal acne in women who choose to use this type of oral contraceptive.


Q: Is Ciclomex-20 a treatment that is usually taken for a short period or long-term?

Ciclomex-20 is designed for long-term, continuous, cyclic administration. It is an established, reversible method of contraception intended to be used for the entire duration that pregnancy prevention is desired.


Q: How does the concentration of Ciclomex-20 (20mg) compare to other available strengths?

Ciclomex-20 contains 20 mu g of the estrogen component, Ethinylestradiol. This is considered a low-dose formulation, as official guidance notes COC doses generally range from 10 mu g to 50 mu g of Ethinylestradiol.


Q: Is Ciclomex-20 known to cause any side effects that last for a long time?

Official warnings highlight the possibility of serious, rare adverse reactions, such as blood clots and liver damage, which are recognized as risks associated with its use. Common side effects, such as nausea or spotting, usually occur initially but tend to lessen or resolve within the first few months of continuous use.


Q: Is feeling unusually tired or drowsy a common reaction to Ciclomex-20?

Official documentation for similar medications indicates unusual tiredness or weakness (fatigue) has been documented as a less common side effect. However, tiredness and drowsiness are not listed among the very common or common adverse reactions for Ciclomex-20.


Q: What signs or symptoms indicate a serious, but rare, adverse reaction to Ciclomex-20?

Serious adverse reactions may be signaled by symptoms such as severe chest pain, sudden shortness of breath, or pain/swelling in the leg. Symptoms of liver injury can include jaundice (yellowing of the skin/eyes).


Q: Do initial side effects when starting Ciclomex-20 typically go away after a few weeks?

Yes, some minor side effects are known to occur when first starting the medication. Official information indicates that initial side effects, such as nausea and irregular bleeding (spotting), often lessen or resolve within the first few months of continuous use.


Q: Does Ciclomex-20 affect mental clarity, focus, or memory?

Regulatory labeling lists mood changes and headaches as common side effects of Ciclomex-20. However, official documentation contains limited direct information regarding effects on mental clarity, focus, or memory.


Q: How long does it usually take for Ciclomex-20 to start providing its intended benefit?

According to official regulatory guidance, Ciclomex-20 typically requires 7 days of continuous use to establish its full intended contraceptive protection. For this reason, regulatory guidance suggests the use of a back-up method during the first seven days of a new regimen.


Q: Does Ciclomex-20 interact with commonly used over-the-counter pain medications?

The regulatory labels for Ciclomex-20 do not list a universal contraindication against common over-the-counter (OTC) pain medications. However, official sources suggest reviewing the full prescribing information for specific guidance on medications like acetaminophen or NSAIDs if they are taken regularly.


Q: Are there any specific foods or beverages that should be avoided while using Ciclomex-20?

Official regulatory guidance suggests avoiding grapefruit and grapefruit juice because they can interfere with the breakdown of the hormones in the body, potentially leading to increased hormone levels and a higher risk of side effects.


Q: Is it generally safe to take Ciclomex-20 alongside other prescription medications for chronic conditions?

Regulatory documents warn that many prescription drugs, particularly those that induce certain liver enzymes, can reduce the effectiveness of Ciclomex-20. This interaction may lead to a need for backup contraception when these medications are taken concurrently.


Q: Does Ciclomex-20 interact with common vitamins, minerals, or herbal supplements?

The official regulatory label specifically calls out the herbal supplement St. John’s wort as a product known to interact with and reduce the effectiveness of Ciclomex-20. Interactions with specific vitamins or minerals are not universally listed, and consultation with a healthcare professional is suggested for guidance.


Q: Is there guidance on whether Ciclomex-20 can affect the results of routine lab tests?

Yes, regulatory guidance includes a section noting that Ciclomex-20 can interfere with the results of certain blood and laboratory tests. These effects relate to the measurement of certain hormones and coagulation factors in the blood.


Q: Is Ciclomex-20 commonly prescribed to older adults or seniors, and are there special considerations?

Ciclomex-20 is not indicated for use in elderly women. Regulatory guidance also includes a strong caution against use by women over 35 years of age who smoke due to a significantly increased cardiovascular risk.


Q: What is the general success rate or effectiveness data reported from the Ciclomex-20 studies?

When used perfectly and consistently according to the regimen, Ciclomex-20 is rated as a highly effective method of contraception. Official regulatory data for similar oral contraceptives typically cites an effectiveness rate between 91% and 99%.


Q: Where can a patient find the official, full regulatory prescribing information for Ciclomex-20?

Official regulatory information is made publicly available by government agencies. Patients can usually find the full Prescribing Information or the Summary of Product Characteristics (SmPC) via searchable portals provided by organizations such as the FDA (DailyMed) or the European Medicines Agency (EMA).


Q: What are some known reasons Ciclomex-20 may not be effective for some individuals?

The most common reasons for a failure to prevent pregnancy are missed pills or incorrect use of the drug regimen. Regulatory labeling also highlights that taking Ciclomex-20 with certain enzyme-inducing medications can significantly reduce its effectiveness.


Q: Does Ciclomex-20 have a specific boxed warning or other major safety statements from regulatory agencies?

Yes, regulatory information often includes a major safety statement. This prominent warning, sometimes referred to as a Boxed Warning, concerns the increased risk of serious cardiovascular events for women who smoke, especially those over 35 years of age.


Q: Are there any warnings about taking Ciclomex-20 if you have a history of seizures?

The regulatory label warns that some medications used to treat seizures (known as anticonvulsants) may reduce the effectiveness of Ciclomex-20. This is because they can increase the breakdown of the contraceptive hormones, which may lead to a need for alternative or backup contraception.

Advertisements

How should Ciclomex-20 be stored and disposed of?

How to Store and Dispose of Ciclomex-20

The storage and disposal of Ciclomex-20 (Ethinylestradiol/Gestodene) must strictly follow official regulatory requirements to ensure product integrity.


Storage Requirements

Condition Requirement
Temperature Store below 30 C (86 F), away from heat.
Protection Keep the tablets protected from light and moisture.
Packaging The tablets must remain in the original blister pack and outer carton until the time of use.

Handling and Safety

Official labeling mandates that Ciclomex-20 must be kept out of reach of children. The product should not be used after the expiration date (EXP) printed on the packaging.

Disposal Instructions

Unused or expired Ciclomex-20 should be discarded using an authorized drug take-back program. If a take-back program is not available, the tablets can be mixed with an unappealing substance (such as used coffee grounds) and sealed in a container before placing in the household trash, following the non-flush list guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Ciclomex-20 found in:

A-Z Index: